UFK Klinikum Südstadt Frauenklinik
Welcome,         Profile    Billing    Logout  
 3 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reimer, Toralf
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
SENOMAC, NCT02240472: Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.

Active, not recruiting
N/A
2700
Europe
Omission of axillary clearance
Karolinska Institutet, The Swedish Research Council, Swedish Cancer Foundation, Nordic Cancer Union
Breast Cancer
12/21
12/26
INSEMA, NCT02466737: Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery

Active, not recruiting
N/A
5505
Europe
no axillary surgery versus SLNB, SLNB versus completion ALND
University of Rostock, German Cancer Aid, German Breast Group
Breast Cancer
08/24
06/25
SENTICOL III, NCT03386734: International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

Active, not recruiting
N/A
989
Europe, Canada, Japan, RoW
SLN biopsy only, SLN biopsy + PLN dissection
Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Cervical Cancer
05/27
05/29
NCT04101851: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST

Active, not recruiting
N/A
350
Europe
omission of SLNB
Toralf Reimer, MD PhD, European Breast Cancer Reseach Association of Surgical Trialists, University Medicine Rostock, Rostock, Germany (sponsor), Else Kröner-Fresenius-Stiftung (funding), German Society of Senology (funding)
Breast Cancer Female, Breast Cancer
01/28
01/28
George, Christian
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Completed
4
89
Europe
Trabectidin (Yondelis)
North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar
Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma
08/23
08/23
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH, ImmunoGen, Inc.
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26

Download Options